Fresenius Kabi
Azeen Roohi James currently serves as the VP, Head of Legal, Business Development and Alliance Management, as well as VP, Chief IP Counsel - Biosimilars US at Fresenius Kabi since February 2020. Prior to this role, Azeen held positions including Associate General Counsel for Intellectual Property at MacroGenics, Inc., Assistant General Counsel for Global IP Biologics at Mylan, and Vice President of Legal - Intellectual Property at Lupin Pharmaceuticals. Azeen's extensive career also features roles as Head of IP for Generics and Biosimilars at Lonza and Principal at A.R. James LLC, along with experience as a Partner at Kenyon & Kenyon and Vice President of Intellectual Property at Barr Laboratories, Inc. Azeen earned a JD from Boston University School of Law, a MS in Organic Chemistry from the University of California, Davis, and a BS in Chemistry from Sonoma State University.
This person is not in any teams
This person is not in any offices
Fresenius Kabi
15 followers
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.